Search results
Showing 1 to 12 of 12 results for selinexor
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Awaiting development Reference number: GID-TA11941 Expected publication date: TBC
Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Awaiting development Reference number: GID-TA12014 Expected publication date: TBC
Awaiting development Reference number: GID-TA11938 Expected publication date: TBC
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Discontinued Reference number: GID-TA10694
This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections